Back

Virus-Like Particles: The Next Frontier in Livestock Gene Editing

von Heyl, T.; Pauli, T. M.; Rieblinger, B.; Schleibinger, S. T.; Liang, W.; Schmauser, A.; Arullmoli, M.; Derrer, P.; Eckstein, A.; Jagana, S.; Gatti Correa, C.; Flisikowski, K.; Flisikowska, T.; Schusser, B.

2026-04-01 genetics
10.64898/2026.03.30.715406 bioRxiv
Show abstract

Pigs and chickens are not only the most important livestock species for global food production but also serve as key model organisms in various research disciplines. The pig is widely used in translational research due to its anatomical and physiological similarity to humans, providing valuable insights into immunology, metabolism, and disease mechanisms. In contrast, the chicken has become an essential model for studies related to poultry health, animal welfare, and developmental biology. Its externally developing embryo offers exceptional accessibility for experimental manipulation. Recent advances in genome editing technologies, particularly CRISPR/Cas9, have further expanded the potential of these species for functional genomic studies, although the efficient delivery of such tools remains a major challenge. By using virus-like particles (VLPs), we have been able to overcome this limitation. Here, we evaluated VLPs as delivery vehicles for genome engineering tools in pigs and chickens, two key livestock species at the human-animal interface. VLP-mediated delivery enabled efficient Cre recombination and high CRISPR/Cas9 editing rates in porcine cells, organoids, and oocytes, particularly when multiplexed. In chickens, VLPs supported robust Cre recombination and Cas9-mediated editing in cell culture, tracheal organ cultures, and in ovo. Reporter VLPs and dCas9 VLPs further demonstrated the versatility of this platform across porcine and avian systems. Together, these findings establish VLPs as an efficient and time-saving strategy for gene editing in livestock, with relevance for animal health, agricultural productivity, and translational One Health research.

Matching journals

The top 13 journals account for 50% of the predicted probability mass.

1
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 0.1%
10.2%
2
Molecular Therapy
71 papers in training set
Top 0.3%
6.4%
3
Nature Communications
4913 papers in training set
Top 35%
4.3%
4
PLOS ONE
4510 papers in training set
Top 39%
3.6%
5
Scientific Reports
3102 papers in training set
Top 36%
3.6%
6
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
3.6%
7
Nucleic Acids Research
1128 papers in training set
Top 6%
3.6%
8
ACS Synthetic Biology
256 papers in training set
Top 1%
3.1%
9
Advanced Science
249 papers in training set
Top 6%
3.1%
10
Cell Discovery
54 papers in training set
Top 2%
2.8%
11
Science China Life Sciences
26 papers in training set
Top 0.6%
2.1%
12
Frontiers in Genetics
197 papers in training set
Top 4%
1.9%
13
BMC Biology
248 papers in training set
Top 0.8%
1.9%
50% of probability mass above
14
Genome Biology
555 papers in training set
Top 4%
1.9%
15
Communications Biology
886 papers in training set
Top 7%
1.8%
16
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 4%
1.8%
17
Cell Reports Methods
141 papers in training set
Top 2%
1.7%
18
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.7%
19
Emerging Microbes & Infections
74 papers in training set
Top 1.0%
1.5%
20
PLOS Pathogens
721 papers in training set
Top 6%
1.5%
21
Cell Reports Physical Science
18 papers in training set
Top 0.3%
1.3%
22
Molecular Therapy Methods & Clinical Development
13 papers in training set
Top 0.1%
1.3%
23
PLOS Genetics
756 papers in training set
Top 10%
1.3%
24
Viruses
318 papers in training set
Top 4%
1.2%
25
Protein & Cell
25 papers in training set
Top 2%
1.0%
26
eLife
5422 papers in training set
Top 51%
1.0%
27
Life Science Alliance
263 papers in training set
Top 1%
0.9%
28
Cell Reports
1338 papers in training set
Top 30%
0.9%
29
Developmental Cell
168 papers in training set
Top 11%
0.9%
30
BMC Genomics
328 papers in training set
Top 4%
0.9%